A pilot data analysis of a metabolomic HPLC-MS/MS study of
patients with COPD

J 2018

A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD

NOVOTNA, B., M. ABDEL-HAMID, V. KOBLIZEK, Michal SVOBODA, Karel HEJDUK et. al.

Basic information

Original name

A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD

Authors

NOVOTNA, B. (203 Czech Republic, guarantor), M. ABDEL-HAMID (414 Kuwait), V. KOBLIZEK (203 Czech Republic), Michal SVOBODA (203 Czech Republic, belonging to the institution), Karel HEJDUK (203 Czech Republic, belonging to the institution), V. REHACEK (203 Czech Republic), J. BIS (203 Czech Republic) and F. SALAJKA (203 Czech Republic)

Edition

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, WROCLAW, WROCLAW MEDICAL UNIV, 2018, 1899-5276

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10103 Statistics and probability

Country of publisher

Poland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.227

RIV identification code

RIV/00216224:14110/18:00103470

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.17219/acem/68763

UT WoS

000432226900014

Keywords in English

amino acids; chronic obstructive pulmonary disease; liquid chromatography-tandem mass spectrometry; carnitine; metabolomics

Abstract

V originále

Background. Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with multiple clinical faces. Metabolomic profiling studies small molecules present in biological samples by combined use of chromatography with mass spectrometry. Objectives. The goal of our work was to perform a high performance liquid chromatography combined with tandem mass spectrometry (HPLC-MS/MS) metabolomic study to compare the concentrations of metabolites in COPD patients and in controls. Material and methods. Participants were recruited at the University Hospital, Hradec Kralove, Czech Republic, with the approval of the ethics committee. The analysis of blood samples was performed at Health Sciences Center (HSC) in Kuwait. The blood samples were analyzed for concentrations of acylcarnitines and amino acids by high performance liquid chromatography (Waters 2690 HPLC; Waters, Milford, USA) and a triple-quadruple tandem mass spectrometer (Quattro LC, Micromass, Manchester, United Kingdom). Results. Groups of 10 subjects with COPD and 10 healthy controls were analyzed. Carnitine analysis showed that the free carnitine to acylcarnitine ratio (CO/AC ratio) was significantly lower in COPD (0.58 mu M/L) compared to the controls (0.73 mu M/L; p = 0.002). The mean C8/C2 ratio in the COPD group was significantly higher (0.03 mu M/L) - in the control group it was 0 mu M/L (p = 0.03). Amino acid analysis showed lower levels of phenylalanine in the COPD group (22.05 mu M/L) compared to the controls (30.05 mu M/L; p = 0.008). The alanine concentrations were significantly lower in the COPD group (173 mu M/L) than in the control group (253 mu M/L; p = 0.001). The pyroglutamate levels were higher in COPD (1.58 mu M/L) than in the controls (1 mu M/L; p = 0.040). Conclusions. The carnitine and acylcarnitine levels in COPD subjects in this study possibly indicate a predisposition to atherosclerosis as a result of inadequate p-oxidation of fatty acids and show the presence of oxidative stress. Furthermore, the high sensitivity to changes in circulating amino acid levels may allow us to detect subclinical malnutrition and take early preventative interventions such as nutritional supplementation and patient education.

Citovat

NOVOTNA, B., M. ABDEL-HAMID, V. KOBLIZEK, Michal SVOBODA, Karel HEJDUK, V. REHACEK, J. BIS and F. SALAJKA. A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE. WROCLAW: WROCLAW MEDICAL UNIV, 2018, vol. 27, No 4, p. 531-539. ISSN 1899-5276. Available from: https://dx.doi.org/10.17219/acem/68763.

@article{1429136,
   author = {Novotna, B. and AbdelandHamid, M. and Koblizek, V. and Svoboda, Michal and Hejduk, Karel and Rehacek, V. and Bis, J. and Salajka, F.},
   article_location = {WROCLAW},
   article_number = {4},
   doi = {http://dx.doi.org/10.17219/acem/68763},
   keywords = {amino acids; chronic obstructive pulmonary disease; liquid chromatography-tandem mass spectrometry; carnitine; metabolomics},
   language = {eng},
   issn = {1899-5276},
   journal = {ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE},
   title = {A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD},
   volume = {27},
   year = {2018}
}

TY  - JOUR
ID  - 1429136
AU  - Novotna, B. - Abdel-Hamid, M. - Koblizek, V. - Svoboda, Michal - Hejduk, Karel - Rehacek, V. - Bis, J. - Salajka, F.
PY  - 2018
TI  - A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD
JF  - ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
VL  - 27
IS  - 4
SP  - 531-539
EP  - 531-539
PB  - WROCLAW MEDICAL UNIV
SN  - 18995276
KW  - amino acids
KW  - chronic obstructive pulmonary disease
KW  - liquid chromatography-tandem mass spectrometry
KW  - carnitine
KW  - metabolomics
N2  - Background. Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with multiple clinical faces. Metabolomic profiling studies small molecules present in biological samples by combined use of chromatography with mass spectrometry. Objectives. The goal of our work was to perform a high performance liquid chromatography combined with tandem mass spectrometry (HPLC-MS/MS) metabolomic study to compare the concentrations of metabolites in COPD patients and in controls. Material and methods. Participants were recruited at the University Hospital, Hradec Kralove, Czech Republic, with the approval of the ethics committee. The analysis of blood samples was performed at Health Sciences Center (HSC) in Kuwait. The blood samples were analyzed for concentrations of acylcarnitines and amino acids by high performance liquid chromatography (Waters 2690 HPLC; Waters, Milford, USA) and a triple-quadruple tandem mass spectrometer (Quattro LC, Micromass, Manchester, United Kingdom). Results. Groups of 10 subjects with COPD and 10 healthy controls were analyzed. Carnitine analysis showed that the free carnitine to acylcarnitine ratio (CO/AC ratio) was significantly lower in COPD (0.58 mu M/L) compared to the controls (0.73 mu M/L; p = 0.002). The mean C8/C2 ratio in the COPD group was significantly higher (0.03 mu M/L) - in the control group it was 0 mu M/L (p = 0.03). Amino acid analysis showed lower levels of phenylalanine in the COPD group (22.05 mu M/L) compared to the controls (30.05 mu M/L; p = 0.008). The alanine concentrations were significantly lower in the COPD group (173 mu M/L) than in the control group (253 mu M/L; p = 0.001). The pyroglutamate levels were higher in COPD (1.58 mu M/L) than in the controls (1 mu M/L; p = 0.040). Conclusions. The carnitine and acylcarnitine levels in COPD subjects in this study possibly indicate a predisposition to atherosclerosis as a result of inadequate p-oxidation of fatty acids and show the presence of oxidative stress. Furthermore, the high sensitivity to changes in circulating amino acid levels may allow us to detect subclinical malnutrition and take early preventative interventions such as nutritional supplementation and patient education.
ER  -

NOVOTNA, B., M. ABDEL-HAMID, V. KOBLIZEK, Michal SVOBODA, Karel HEJDUK, V. REHACEK, J. BIS and F. SALAJKA. A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD. \textit{ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE}. WROCLAW: WROCLAW MEDICAL UNIV, 2018, vol.~27, No~4, p.~531-539. ISSN~1899-5276. Available from: https://dx.doi.org/10.17219/acem/68763.

Detailed Information on Publication Record